0001179110-12-015715.txt : 20121105 0001179110-12-015715.hdr.sgml : 20121105 20121105202655 ACCESSION NUMBER: 0001179110-12-015715 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20121101 FILED AS OF DATE: 20121105 DATE AS OF CHANGE: 20121105 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Metza Kristen CENTRAL INDEX KEY: 0001314870 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19731 FILM NUMBER: 121181548 MAIL ADDRESS: STREET 1: 333 LAKESIDE DRIVE CITY: FOSTER CITY STATE: CA ZIP: 94404 FORMER NAME: FORMER CONFORMED NAME: Anderson Kristen Metza DATE OF NAME CHANGE: 20050121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: GILEAD SCIENCES INC CENTRAL INDEX KEY: 0000882095 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943047598 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 6505743000 MAIL ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 4 1 edgar.xml FORM 4 - X0306 4 2012-11-01 1 0000882095 GILEAD SCIENCES INC GILD 0001314870 Metza Kristen GILEAD SCIENCES, INC. 333 LAKESIDE DRIVE FOSTER CITY CA 94404 0 1 0 0 SVP, Human Resources Common Stock 2012-11-01 4 M 0 14000 38.17 A 39305 D Common Stock 2012-11-01 4 M 0 14000 47.51 A 53305 D Common Stock 2012-11-01 4 M 0 2000 43.15 A 55305 D Common Stock 2012-11-01 4 S 0 27200 67.6753 D 28105 D Common Stock 2012-11-01 4 S 0 2800 68.1779 D 25305 D Non-Qualified Stock Option (Right to Buy) 38.17 2012-11-01 4 M 0 14000 0 D 2021-01-20 Common Stock 14000 19600 D Non-Qualified Stock Option (Right to Buy) 43.15 2012-11-01 4 M 0 2000 0 D 2018-01-30 Common Stock 2000 3500 D Non-Qualified Stock Option (Right to Buy) 47.51 2012-11-01 4 M 0 14000 0 D 2020-01-28 Common Stock 14000 12600 D The exercise and sale transactions are pursuant to a Rule 105b-1 trading plan established by Ms. Metza on February 22, 2011. The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Sale prices reported for the transactions reported here range from $67.12 to $68.12. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Sale prices reported for the transactions reported here range from $68.13 to $68.25. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. /s/ Gregg H. Alton by Power of Attorney for Kristen M. Metza 2012-11-05